What side effects can Rinvoq (upadacitinib) cause in psoriatic arthritis?
Rinvoq is a Janus kinase (JAK) inhibitor used for psoriatic arthritis, and its side effects largely match the known safety profile of JAK inhibitors. Commonly reported effects include upper respiratory infections (like colds), nausea, and injection-site or administration-related discomfort (depending on regimen) [1].
More serious risks are also part of the label and are especially important to monitor, including infections that can become severe, blood count changes (such as low white blood cells or anemia), and lab abnormalities like increased cholesterol or liver enzyme elevations [1].
Which serious side effects should patients watch for?
Patients are typically advised to seek medical care promptly if they develop signs of a serious infection (for example, fever, persistent cough, or worsening fatigue), because JAK inhibitors can increase infection risk [1].
Other serious warnings can include increased risk of major cardiovascular events, blood clots, and malignancies (cancers), along with gastrointestinal perforation (a rare but serious condition) in higher-risk patients [1].
What infection risks come with Rinvoq?
Because Rinvoq targets immune signaling pathways, it can make infections more likely or more severe than in people not taking it. The risk is generally higher in people with prior or recurrent infections, older age, or other immunosuppressive therapies [1].
If a patient develops suspected infection symptoms, clinicians often evaluate whether Rinvoq should be held until the infection is controlled.
How do blood tests and lab monitoring work on Rinvoq?
Clinicians usually monitor for treatment-related lab changes, which can include:
- Low blood counts (for example, neutrophils or lymphocytes)
- Liver enzyme increases
- Lipid increases (cholesterol changes)
These monitoring steps are part of standard JAK inhibitor safety management and are intended to catch problems early [1].
Does Rinvoq have different side effects than other psoriatic arthritis treatments?
Rinvoq’s side effects are distinct from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, which have different risk patterns (for example, stomach bleeding or blood sugar effects). Versus other advanced therapies (like TNF inhibitors or IL-17/IL-23 inhibitors), the key differentiator is that Rinvoq is a small-molecule immune modulator with JAK inhibitor class risks, particularly infection and blood-count/lab changes [1].
What increases risk for side effects?
Risk tends to rise in people with:
- Active or chronic infections
- Older age
- History of blood clots, major cardiovascular events, or certain cancers
- Concurrent use of other immunosuppressive medications
These factors affect clinician decision-making on dosing, monitoring frequency, and whether alternative treatments are safer [1].
Are there drug interaction issues that affect side effects?
Yes. Because Rinvoq is metabolized via drug-processing pathways, some medications can increase or decrease Rinvoq exposure, which can raise side effect risk or reduce effectiveness. Patients are typically instructed to tell their prescribers about all medicines, including antibiotics, antifungals, antivirals, seizure medicines, and herbal supplements like St. John’s wort [1].
Pregnancy, breastfeeding, and fertility concerns
If pregnancy is possible, patients usually need counseling about use and timing because immunomodulatory therapies can pose fetal risk. Similar guidance applies to breastfeeding decisions; clinicians weigh medication exposure against the benefits of treatment [1].
---
Source
[1] https://www.drugs.com/rinvoq.html